如何规范报告复杂干预性系统评价和Meta分析:PRISMA-CI解读

详细信息    查看全文 | 推荐本文 |

英文篇名：An Introduction of Preferred Reporting Items for Systematic Reviews and Meta-Analysis for Complex Interventions 作者：田金徽 ; 马文娟 ; 苟铃珠 ; 陈吉 ; 孙月 ; 王盼杰 ; 张俊华 英文作者：TIAN Jin-hui;MA Wen-juan;GOU Ling-zhu;CHEN Ji;SUN Yue;WANG Pan-jie;ZHANG Jun-hua;Evidence-based Medicine Center,School of Basic Medical Sciences,Lanzhou University;Key Laboratory of Clinical Translational Research and Evidence-based Medicine of Gansu Province;The Second Clinical Medical College of Lanzhou University;School of Nursing of Lanzhou University;The First Clinical Medical College of Lanzhou University;Centre for Evidence-based Medicine Tianjin University of Traditional Chinese Medicine; 关键词：复杂干预 ; 系统评价 ; 复杂干预性系统评价和Meta分析报告规范(PRISMA-CI) ; Meta分析 英文关键词：Complex Interventions;;Systematic Reviews;;Preferred Reporting Items for Systematic Reviews and Meta-Analysis for Complex Interventions(PRISMA-CI);;Meta-Analysis 中文刊名：YAPJ 英文刊名：Chinese Journal of Drug Evaluation 机构：兰州大学循证医学中心兰州大学基础医学院;甘肃省循证医学与临床转化重点实验室;兰州大学第二临床医学院;兰州大学护理学院;兰州大学第一临床医学院;天津中医药大学循证医学中心; 出版日期：2018-02-25 出版单位：中国药物评价 年：2018 期：v.35 语种：中文; 页：YAPJ201801020 页数：4 CN：01 ISSN：10-1056/R 分类号：65-68

摘要

系统评价和Meta分析优先报告的条目(Preferred Reporting Items for Systematic Review and Meta-analysis,PRISMA)系列报告规范的陆续发表在一定程度上规范了系统评价/Meta分析报告,本文主要介绍PRISMA-CI的报告条目,并对其进行解读,期望为国内研究人员报告复杂干预性系统评价和Meta分析提供借鉴和参考。
        The preferred reporting items for systematic review and Meta-analysis guidelines were published to improve the reporting of systematic reviews and Meta-analysis. The study mainly introduced and interpreted the items of PRISMA-CI,in order to help domestic researchers to perform and report the systematic review and Meta-analysis of complex interventions by PRISMA-CI.

引文

[1]Campbell M,Fitzpatrick R,Haines A,et al.Framework for design and evaluation of complex interventions to improve health[J].BMJ,2000,321(7262):694-696.
    [2]Medical research council.Framework for development and evaluation of RCTs for complex interventions to improve health[M].London:Medical research council,2000:1-18.
    [3]Meyer TJ,Van Kooten D,Marsh S,et al.Reduction of polypharmacy by feedback to clinicians[J].J Gen Intern Med,1991,6(2):133-136.
    [4]Guise JM,Butler ME,Chang C,et al.AHRQ series on complex intervention systematic reviews-paper 6:PRISMA-CI extension statement and checklist[J].J Clin Epidemiol,2017,90:43-50.
    [5]Guise JM,Butler ME,Chang C,et al.AHRQ series on complex intervention systematic reviews-paper 7:PRISMA-CI elaboration and explanation[J].J Clin Epidemiol,2017,90:51-58.
    [6]李先涛,胡镜清,刘保延,等.复杂干预概述[J].天津中医药大学学报,2013,32(4):250-252.
    [7]陈新林,李先涛,胡镜清,等.复杂干预的设计和评价方法[J].辽宁中医药大学学报,2013,15(4):81-83.
    [8]田金徽,葛龙,赵晔,等.网状Meta分析优先报告条目:PRISMA扩展声明解读[J].中国药物评价,2015,32(5):266-272.
    [9]赵晔,葛龙,张珺,等.单个病例数据系统评价/Meta分析优先报告条目简介[J].中国药物评价,2015,32(5):262-265.
    [10]张珺,葛龙,赵晔,等.PRISMA系列报告规范简介[J].中国药物评价,2015,32(5):257-261.